SCHEMBL3560347

SCHEMBL3560347

Cc1ccccc1C(NC(=O)Nc1ccc(Cl)cc1)C(=O)NC1=CCC(=NN(C)C)C=C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.38
NPC1 O15118 3/20 0.38
UTS2R Q9UKP6 6/20 0.37
CNR1 P21554 3/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KCNJ6 P48051 1/20 0.34
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
IDH1 O75874 1/20 0.34
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566489 0.92 UTS2R (0.37) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3564411 0.91 CNR1 (0.36) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3573284 0.90 CNR1 (0.36) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3564560 0.90 UTS2R (0.36) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3564975 0.89 LMNA (0.40) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3559267 0.89 FPR2 (0.42) UTS2RCNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3566653 0.86 CNR1 (0.36) RAB9ANPC1CNR1MEN1KMT2A
SCHEMBL3567171 0.84 HTT (0.42) RAB9ANPC1UTS2RCNR1MEN1
SCHEMBL3570284 0.81 FPR2 (0.43) RAB9ANPC1CNR1MEN1KMT2A
SCHEMBL3567078 0.80 MAPT (0.43) NPC1UTS2RCNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 RAB9A 2958/4885NPC1 1325/4885UTS2R 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.